Y.D. More Investments Ltd Has $17.90 Million Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Y.D. More Investments Ltd cut its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 9.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,254,591 shares of the company’s stock after selling 126,959 shares during the period. Takeda Pharmaceutical comprises approximately 3.6% of Y.D. More Investments Ltd’s holdings, making the stock its 6th largest holding. Y.D. More Investments Ltd’s holdings in Takeda Pharmaceutical were worth $17,903,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of TAK. GAMMA Investing LLC bought a new position in shares of Takeda Pharmaceutical in the 4th quarter valued at about $28,000. Lindbrook Capital LLC grew its holdings in Takeda Pharmaceutical by 40.6% during the fourth quarter. Lindbrook Capital LLC now owns 4,065 shares of the company’s stock worth $58,000 after purchasing an additional 1,174 shares during the period. Hexagon Capital Partners LLC grew its position in shares of Takeda Pharmaceutical by 65.7% in the third quarter. Hexagon Capital Partners LLC now owns 5,548 shares of the company’s stock valued at $86,000 after purchasing an additional 2,199 shares during the last quarter. Blue Trust Inc. raised its position in shares of Takeda Pharmaceutical by 91.1% in the fourth quarter. Blue Trust Inc. now owns 5,837 shares of the company’s stock valued at $91,000 after buying an additional 2,782 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Takeda Pharmaceutical in the 4th quarter valued at $85,000. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock traded up $0.11 during midday trading on Wednesday, hitting $13.19. 1,293,552 shares of the company traded hands, compared to its average volume of 1,799,791. Takeda Pharmaceutical Company Limited has a 12 month low of $13.01 and a 12 month high of $17.11. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.55 and a current ratio of 1.06. The stock has a market cap of $41.74 billion, a price-to-earnings ratio of 19.83, a PEG ratio of 3.00 and a beta of 0.53. The firm’s fifty day moving average price is $13.99 and its 200-day moving average price is $14.15.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, February 1st. The company reported $0.51 earnings per share for the quarter. The firm had revenue of $7.52 billion for the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a return on equity of 12.57%. As a group, sell-side analysts forecast that Takeda Pharmaceutical Company Limited will post 1.5 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.